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ABSTRACT 
In this study, we illustrate computer aided drug design of new benzothiazole and pyrim-
ido[2,1-b]benzothiazole derivatives as epidermal growth factor receptor tyrosine kinase 
(EGFR-TK) inhibitors. Compounds 1-5 were screened at NCI, USA, for antitumor activity 
against non-small cell lung cancer (NCI-H522), colon cancer (HCT-116, HCT-15 and HT29) 
and breast cancer (MDA-MB-468 and MDA-MB-231/ATCC) cell lines in which EGFR is 
overexpressed in varying levels. Results indicated that these compounds are more potent anti-
tumor agents compared to erlotinib against HT29 and MDA-MB-231/ATCC cell lines. Com-
pound 3 showed GI50 value of 22.3 nM against NCI-H522 cell line, while erlotinib exhibited 
GI50 value of 1 µM against the same cell line. In addition, these compounds were studied for 
their EGFR tyrosine kinase inhibitory activity. Virtual screening utilizing molecular modeling 
and QSAR techniques enabled the understanding of the pharmacophoric requirements for an-
titumor activity. Docking the designed compounds into the ATP binding site of EGFR-TK 
domain was done to predict the analogous binding mode of these compounds to the EGFR-
TK inhibitors.  
 
Keywords: benzothiazoles, pyrimidobenzothiazoles, antitumor activity, EGFR tyrosine  
kinase inhibitory activity, molecular modeling 
 
 
 
INTRODUCTION 
Protein kinases were proved to be a via-
ble target for anticancer drug development 
(Wu et al., 2012; Levitzki, 2012; Cheng et 
al., 2011). They are the second most im-
portant drug targets after G protein coupled 
receptors (GPCR’s) (Cohen, 2002). Kinases 
are involved in many pathophysiological 
problems especially cancers where their 
overexpression can lead to different types of 
malignancies (Roymans and Slegers, 2001; 
Malumbres and Barbacid, 2007). In addition, 
EGFR-TK is one of the most important ki-
nases that plays a fundamental role in signal 
transduction pathways (Peng-Cheng et al., 
2010). EGFR and its ligands, epidermal 
growth factor (EGF) and transforming 
growth factor-α (TGF-α) have been implicat-
ed in numerous tumors of epithelial origin 
(Ullrich and Schlessinger, 1990). Therefore, 
the design of inhibitors that target EGFR-TK 
is an attractive approach for the development 
of new therapeutic agents (Bridges, 2001; 
Grünwald and Hidalgo, 2003). Gefitinib 
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(ZD-1839, Iressa) (Tamura and Fukuoka, 
2005) and erlotinib (OSI-774, Tarceva) 
(Reck et al., 2010; Smith, 2005) were ap-
proved as EGFR-TK inhibitors for the treat-
ment of non-small cell lung cancer.  
Benzothiazole derivatives constitute an 
important class of therapeutic agents in me-
dicinal chemistry. Literature survey revealed 
that this nucleus is associated with diverse 
pharmacological effects including, antitumor 
(Shi et al., 2012; Elzahabi, 2011; Saeed et 
al., 2010; Hu et al., 2010; Al-Soud et al., 
2008; Mortimer et al., 2006; Brantley et al., 
2006) and antioxidant (Cressier et al., 2009) 
activities. Moreover, pyrimido[2,1-b]benzo-
thiazoles have also been extensively investi-
gated for their pharmacological uses (Sahu et 
al., 2012; Prasad et al., 2012; Shendarkar et 
al., 2011; El-Sherbeny, 2000), some of these 
compounds showed antitumor activity (El-
Sherbeny, 2000). Taking all the above find-
ings into consideration and in searching for 
new compounds of potent antitumor activity, 
we report herein the in vitro antitumor evalu-
ation of new benzothiazole and pyrimido-
[2,1-b]benzothiazole derivatives bearing py-
razole and oxazole moieties (Figure 1) 
against non-small cell lung cancer (NCI-
H522), colon cancer (HCT-116, HCT-15 and 
HT29) and breast cancer (MDA-MB-468 
and MDA-MB-231/ATCC) cell lines in 
which EGFR is overexpressed in varying 
levels. Also, their EGFR tyrosine kinase in-
hibitory activity was studied, along with 
their docking into the ATP binding site of 
EGFR-TK domain.  
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  Figure 1: Structure of compounds 1-5 
RATIONAL AND DESIGN 
Quinazolines have emerged as a versatile 
template for inhibition of a diverse range of 
receptor tyrosine kinases. EGFR is the most 
widely studied receptor of tyrosine kinases 
and gefitinib was the first inhibitor of this re-
ceptor to be approved for the treatment of 
non-small cell lung cancer refractory to prior 
chemotherapeutic intervention (Ballard et al., 
2006; Ranson, 2004). Subsequent research 
aimed at further exploration of the SAR of 
this novel template, led to the discovery of 
highly selective compounds that target 
EGFR. Benzothiazoles act via competing 
with ATP for binding at the catalytic domain 
of EGFR-TK (Noolvi et al., 2012). The char-
acteristic features of ATP binding site are; 
adenine region which contains two key hy-
drogen bonds formed by the interaction of 
N1 and N6 of the adenine ring, many potent 
inhibitors use one of these hydrogen bonds, 
sugar pocket which is a hydrophilic region, 
hydrophobic regions and channels, although 
not used by ATP but play an important role 
in inhibitor selectivity and binding affinity. 
In addition, phosphate binding region which 
is largely solvent exposed, can be used for 
improving inhibitor selectivity (Fabbro et al., 
2002) (Figure 2). 
In this study, the authors present a new 
subfamily of compounds containing benzo-
thiazole core as EGFR-TK inhibitors. Our 
strategy is directed toward designing a varie-
ty of ligands which are structurally similar to 
the basic skeleton, 4-anilinoquinazoline of 
tinibs (erlotinib and gefitinib) with diverse 
chemical properties (Figure 3). Accordingly, 
we replaced quinazoline ring with benzothia-
zole since both rings are isosteric with ade-
nine portion of ATP and can mimic the ATP 
competitive binding regions of EGFR-TK. 
 
MATERIALS AND METHODS 
Source of compounds 
The benzothiazole and pyrimido[2,1-
b]benzothiazole derivatives 1-5 investigated 
in this study were previously synthesized and  
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Figure 2: The molecular surface representation 
of the ATP-binding site which consists of adenine 
region, hydrophobic regions I and II, sugar pock-
et and phosphate binding region 
 
 
 
Figure 3: Reported antitumor quinazolines and 
proposed compounds; (A) benzothiazole deriva-
tives; (B) pyrimido[2,1-b]benzothiazole deriva-
tives 
 
 
characterized (Gabr et al., 2014). Their 
chemical names are: 
 2-(5-Amino-4-cyano-1H-pyrazol-1-yl)-N-
(6-chlorobenzothiazol-2-yl)acetamide (1) 
 N-(6-Chlorobenzothiazol-2-yl)-2-(3-
methyl-5-phenyl-1H-pyrazol-1-yl) 
acetamide (2) 
 8-Chloro-4-(3,5-dioxopyrazolidine-1-
carbonyl)-2H-pyrimido[2,1-b]benzo- 
thiazol-2-one (3) 
 4-(5-Amino-3-oxo-2,3-dihydro-1H-
pyrazole-1-carbonyl)-8-chloro-2H-
pyrimido[2,1-b]benzothiazol-2-one (4) 
 8-Chloro-4-(5-thioxo-4,5-dihydro-
[1,3,4]oxadiazol-2-yl)-2H-pyrimido[2,1-
b]benzothiazol-2-one (5) 
In vitro antitumor evaluation 
Compounds 1-5 were evaluated for their 
antitumor activity in accordance with the 
current protocol of the National Cancer Insti-
tute (NCI), USA. They displayed lethal ac-
tivity against non-small cell lung cancer 
(NCI-H522), colon cancer (HCT-116, HCT-
15 and HT29) and breast cancer (MDA-MB-
468 and MDA-MB-231/ATCC) cell lines in 
which EGFR is overexpressed in varying 
levels. They passed the preliminary in vitro 
one-dose anticancer assay and were further 
evaluated at five dose level screening. The 
human tumor cell lines of the cancer screen-
ing panel were grown in RPMI 1640 medi-
um containing 5 % fetal bovine serum and 
2 mM L-glutamine. For a typical screening 
experiment, cells were inoculated into mul-
tiwell microtiter plates at plating densities 
ranging from 5,000 to 40,000 cells/well de-
pending on the doubling time of individual 
cell lines. After cell inoculation, the micro-
titer plates were incubated at 37° C, 5 % 
CO2, 95 % air and 100 % relative humidity 
for 24 hrs and then two plates of each cell 
line were fixed in situ with trichloroacetic 
acid (TCA) to represent a measurement of 
the cell population for each cell line at the 
time of compound addition. The tested com-
pounds were solubilized in DMSO at 400-
fold the desired final maximum test concen-
tration and stored frozen prior to use. At the 
time of compound addition, an aliquot of 
frozen concentrate was thawed and diluted to 
twice the desired final maximum test con-
centration with complete medium containing 
50 mg/mL gentamicin. Additional 4-, 10-
fold or 1/2 log serial dilutions were made to 
provide a total of five compound concentra-
tions plus control. Aliquots of 100 mL of 
these dilutions were added to the appropriate 
microtiter wells already containing 100 mL 
of medium, resulting in the required final 
compound concentrations. Following com-
pound addition, the plates were incubated for 
additional 48 hrs at 37° C, 5 % CO2, 95 % 
air, and 100 % relative humidity. For adher-
ent cells, the assay was terminated by the 
addition of cold TCA. Cells were fixed in 
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situ by gentle addition of 50 mL of cold 
50 % (w/v) TCA (final concentration, 10 % 
TCA) and incubated for 60 min at 4° C. The 
supernatant was discarded, and the plates 
were washed five times with tap water and 
air dried. Sulforhodamine B (SRB) solution 
(100 mL) at 0.4 % (w/v) in 1 % acetic acid 
was added to each well, and plates were 
incubated for 10 min at room temperature. 
After staining, unbound dye was removed by 
washing five times with 1 % acetic acid and 
the plates were air dried. Bound stain was 
subsequently solubilized with 10 mM trizma 
base and the absorbance was read on an 
automated plate reader at a wavelength of 
515 nm (Grever et al., 1992; Boyd and Paull, 
1995; Monks et al., 1991). GI50 values were 
calculated for each cell line (Table 1). 
 
EGFR tyrosine kinase assay 
Compounds 1-5 were dissolved in 
DMSO and tested at a single concentration 
of 100 µM. They were then added to reaction 
plates containing the EGFR tyrosine kinase 
in assay buffer [20 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 
pH 7.5, 10 mM MgCl2, 1 mM ethylene gly-
col tetraacetic acid (EGTA), 0.02 % Brij35, 
0.02 mg/mL bovine serum albumin (BSA), 
0.1 mM Na3VO4, 2 mM dithiothreitol 
(DTT), 1 % DMSO]. Reactions were initia-
ted by addition of a mixture of ATP (Sigma, 
St. Louis MO) and 33P ATP (Perkin Elmer, 
Waltham MA) to a final concentration of 
10 μM. Reactions were carried out at room 
temperature for 120 min, followed by spot-
ting of the reactions onto P81 ion exchange 
filter paper (Whatman Inc., Piscataway, NJ). 
Unbound phosphate was removed by exten-
sive washing of filters in 0.75 % phosphoric 
acid (Ma et al., 2008). Kinase activity data 
was reported as the percent remaining enzy-
me activity after subtraction of enzyme inhi-
bitory activity of DMSO control reactions as 
background. Results are presented as percen-
tage enzyme inhibition and compared to 
staurosporine as a reference EGFR-TK inhi-
bitor (Table 2). 
 
Molecular modeling and computational 
studies 
Protein structure preparation  
The crystal structure of EGFR kinase 
domain (PDB ID: 1M17) in complex with an 
irreversible inhibitor was obtained from the 
protein data bank (PDB; http://www.rcsb.-
org/pdb/home/home.do). 
Refinement of crude PDB structure of re-
ceptor was performed. Polar hydrogens were 
added, Kollman charges were assigned and 
atomic solvation parameters were added, the 
internal degrees of freedom and torsions 
were set for all the designed small mole-
cules. The optimized receptor was then saved 
as mol file and used for docking simulation.  
 
 
Table 1: GI50 values (µM) of compounds 1-5 and erlotinib over the selected cancer cell lines 
Subpanel tumor cell lines 
Comp. 
No.  
Breast cancer Colon cancer Non-small cell lung cancer 
MDA-MB-
231/ATCC
MDA-MB-
468 HT-29 HCT-15 HCT-116 NCI-H522 
2.24 
0.387 
0.604 
0.304 
1.88 
4.17 
1.31 
1.87 
0.148 
0.0691  
2.4 
0.951 
0.466 
0.284 
3.46 
10.3 
1.48 
2.06 
0.177 
1.85 
12.6 
1.45 
1.89 
0.165 
2.36 
0.191 
0.154 
0.0223 
0.145 
2.43 
1 
2 
3 
4 
5  
6.31  0.126  63.1  3.98  6.31  1.0 Erlotinib 
 
EXCLI Journal 2014;13:573-585 – ISSN 1611-2156 
Received: February 28, 2014, accepted: May 08, 2014, published: May 26, 2014 
 
 
577 
Table 2: Percentage EGFR-TK inhibitory activity 
of compounds 1-5 
Comp. No. % EGFR-TK Inhibitiona,b 
IC50 (nM)  
Staurosporinec
1 70.58 
50.33 
2 60.76 
3 42.44 
4 46.19 
5 58.66 
Staurosporine 97.87 
Bold value represent the best result in % EGFR-TK inhibition. 
a Compounds were tested in duplicate at a single dose of 100 
µM and the reported % EGFR-TK inhibition represent the 
mean of the two results. 
b Results are calculated after subtraction of DMSO activity.  
c Staurosporine was used as a reference compound and was 
tested with a 10-point 3-fold dilution series starting at 20 µM. 
 
Ligand structure prepartion 
The 2D structures of the compounds 
were built and then converted into the 3D 
with the help of vLife MDS 3.0 software. 
The 3D structures were then energetically 
minimized up to the rms gradient of 0.01 
using CHARMM22 force field. All conform-
ers were then energetically minimized up to 
the rms gradient of 0.01 and then saved in 
separate folder.  
Docking protocol  
Docking simulation was done by Swiss-
Dock software (Grosdidier et al., 2011). All 
the conformers were virtually docked at the 
defined cavity of the receptor. The number 
of placements was fixed at 30 placements 
and the rotation angle was fixed at 30°. By 
rotation angle, the ligand gets rotated for 
different poses. By placements, the method 
will check all the 30 possible placements 
into the active site pocket and results out few 
best placements out of 30. For each ligand, 
all the conformers with their best placements 
and their dock score will be saved in output 
folder. The method also highlights the best 
placement of the best conformer of each 
ligand which is having the best (minimum) 
dock score value. After docking simulation, 
the best docked conformer of each ligand 
and receptor was merged and its complexes 
were then energetically optimized by 
defining the radius of 10 Å measured from 
the docked ligand. 
 
RESULTS AND DISCUSSION 
In vitro antitumor screening  
Compounds 1-5 were evaluated for their 
antitumor activity in accordance with the 
current protocol of the National Cancer 
Institute (NCI), USA (Grever et al., 1992; 
Boyd and Paull, 1995; Monks et al., 1991). 
The data was reported as mean-graph of the 
percentage growth of the treated cells, and 
presented as percentage growth inhibition 
(GI%). They were initially screened at a 
single dose (10 µM) in the full NCI 60 cell 
lines panel assay. Results demonstrated that 
they satisfied the predetermined threshold 
inhibition criteria so they were carried over 
by the NCI for the five-dose screening. Non-
small cell lung cancer (NCI-H522), colon 
cancer (HCT-116, HCT-15 and HT29) and 
breast cancer (MDA-MB-468 and MDA-
MB-231/ATCC) cell lines were incubated 
with five concentrations (0.01–100 µM) of 
each compound and were used to create log 
concentration - % growth inhibition curves. 
The GI50 values of compounds 1-5 and 
erlotinib against the selected cancer cell lines 
are listed in Table 1. Results indicated that 
these compounds are more potent antitumor 
agents compared to erlotinib against colon 
cancer (HT29) and breast cancer (MDA-MB-
231/ATCC) cell lines. Compound 3 
exhibited GI50 value of 22.3 nM against non-
small cell lung cancer (NCI-H522) cell line 
while compound 5 showed GI50 value of 
69.1 nM against breast cancer (MDA-MB-
468) cell line. Moreover, compound 4 
displayed potent antitumor activity with GI50 
values in submicromolar range against all 
tested cancer cell lines. 
 
EGFR tyrosine kinase assay 
In vitro profiling of compounds 1-5 was 
performed at Reaction Biology Corporation 
to assess their inhibitory activity of EGFR-
TK. Kinase activity was assessed using Hot 
Spot technology (Ma et al., 2008), a miniatu-
rized radioisotope-based filter binding assay. 
EXCLI Journal 2014;13:573-585 – ISSN 1611-2156 
Received: February 28, 2014, accepted: May 08, 2014, published: May 26, 2014 
 
 
578 
Kinase activity data was reported as the per-
centage remaining enzyme activity after 
subtraction of enzyme inhibitory activity of 
DMSO control reactions as background. 
Results are presented as percentage enzyme 
inhibition and compared to staurosporine as 
a reference EGFR-TK inhibitor (Table 2). 
Compound 1 showed the highest inhibitory 
activity against EGFR-TK with percentage 
enzyme inhibition value of 70.58. The 
attempt to improve hydrophobic interaction 
via incorporation of an extra phenyl moiety 
resulted in decreased inhibitory activity 
(compound 2). Furthermore, combination of 
[1,3,4]oxadiazole moiety with the pyrimido-
[2,1-b]benzothiazole nucleus increased the 
activity over the other analogs with pyrazole 
and pyrazolidine moieties (compare 5 versus 
3 and 4). 
 
Molecular modeling and computational 
studies 
Overactivation of receptor tyrosine kina-
se (RTK) signaling pathways is strongly as-
sociated with carcinogenesis. Thus, it is be-
coming increasingly clear that impaired de-
activation of RTKs may be an oncogenic dri-
ver of cancer (Kristi et al., 2004). On this ba-
sis, Computer-Aided Drug Design (CADD) 
tools were used to identify the interaction 
between the newly synthesized compounds 
and the active site of EGFR-TK in compari-
son to erlotinib as a reference EGFR-TK in-
hibitor. A representation of our workflow is 
shown in Figure 4.  
Kinase inhibitors should contain the 
following features to gain selectivity and 
potency (Zhang et al., 2009): 
 A portion that closely mimics ATP 
molecule and one to three hydrogen 
bonds with the amino acids located in the 
hinge region of the target kinases, as in 
erlotinib (Reck et al., 2010), lapatinib 
(Wainberg et al., 2010) and gefitinib 
(Yun et al., 2007). 
 An additional hydrophobic binding site 
which is directly adjacent to the ATP 
binding site (allosteric site), as in imati-
nib (Cherry and Williams, 2004) and 
sorafenib (Whittaker et al., 2010). How-
ever, other mechanism could be achieved 
through binding outside the ATP binding 
site at an allosteric site (Weisberg et al., 
2007) and by forming irreversible 
covalent bond to the kinase active site 
(Sridhar et al., 2003; Sharma et al., 
2009). In the present work, erlotinib 
binding mode to EGFR-TK is studied 
and the design of the newly synthesized 
compounds is based on the essential 
chemical features required for erlotinib 
binding affinity to EGFR-TK. 
Similarity-based virtual screening 
Similarity methods may be the simplest 
and most widely used tools for ligand-based 
virtual screening of chemical databases, 
where functionally similar molecules are 
sought by searching molecular databases for 
structurally similar molecules. These 
methods can be categorized as 2D and 3D 
similarity methods. However, the most 
common approaches are based on the 2D 
fingerprints, with the similarity between a 
reference structure and a database structure. 
The synthesized compounds in SDF for-
mat were submitted to ReverseScreen3D ser-
ver (Kinnings and Jackson, 2011), the server 
uses reverse virtual screening (VS) method 
called ReverseScreen3D, it is a 2D finger-
print-based method to select a ligand tem-
plate from each unique binding site of each 
 
 
Figure 4: Virtual screening (VS) workflow 
EXCLI Journal 2014;13:573-585 – ISSN 1611-2156 
Received: February 28, 2014, accepted: May 08, 2014, published: May 26, 2014 
 
 
579 
protein with a target database. The target 
database contains only the structurally deter-
mined bioactive conformations of known 
ligands. The 2D comparison is followed by a 
3D structural comparison to the selected 
query ligand using a geometric matching 
method in order to priotrize each target 
binding site in the database. The output in 
the form of a list of the 2D and 3D scores for 
protein tyrosine kinase (cluster no. 14836) is 
listed in Table 3. Compound 4 showed the 
highest 3D score value of 0.573 which 
comes in accordance with the biological 
data. 
3D Pharmacophore elucidation 
A 3-dimensional pharmacophore is defi-
ned as a critical geometric arrangement of 
molecular features forming a necessary but 
not sufficient condition for biological 
activity (Mason et al., 2001). 3D Pharmaco-
phore designing methods take into account 
both the 3-dimensional structures and bind-
ing modes of receptors and inhibitors in 
order to identify regions that are favorable 
for specific receptor-inhibitor interaction. 
The description of the receptor-inhibitor 
interaction pattern is determined by a correl-
ation between the characteristic properties of 
the inhibitors and their biochemically 
determined enzymatic activity. 
LigandScout, a program that allows the 
automatic construction and visualization of 
3D pharmacophore from structural data of 
protein-ligand complex, was used in this stu-
dy to create a pharmacophore for the mode 
of action of erlotinib, which prevents acti-
vation of EGFR kinase (Wolber and Langer, 
2005). The model (Figure 5) was created 
automatically by overlaying pharmacophoric 
features gathered from the crystal structure 
of EGFR kinase domain (PDB ID: 1M17) in 
complex with erlotinib (PDB; http://www.-
rcsb.org/pdb/home/home.do).  
 
 
 
 
 
Figure 5: (A) The crystal structure of EGFR kinase domain (PDB ID: 1M17) in complex with erlotinib 
was obtained from the protein data bank (PDB; http://www.rcsb.org/pdb/home/home.do). (B) 
LigandScout 3D proposed docking pose for erlotinib in the ATP binding site of EGFR kinase domain. 
(C) The 3D pharmacophore of erlotinib (in ball and stick representation); The pharmacophore color 
coding is red for hydrogen acceptor, yellow for hydrophobic regions and green for hydrogen donors. 
(D) The final 3D pharmacophore model for the EGFR kinase domain 
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The investigated pharmacophoric fea-
tures included; hydrogen bond donors and 
acceptors as directed vectors, positive and 
negative ionizable regions as well as lipophi-
lic areas that are represented by spheres. Ac-
cording to the pharmacophore generated by 
LigandScout, the minimal structural require-
ments for antitumor activity consist of a 
hydrophobic region attached to heterocyclic 
ring which fits into ATP binding site, two 
hydrogen bond acceptors and one hydrogen 
bond donor. The 3D alignment of the phar-
macophoric features of each of the syn-
thesized compounds and the 3D pharma-
cophore of erlotinib binding pose showed 
that these compounds possess similar phar-
macophoric features required for activity. A 
pharmacophore score listed in Table 3 was
calculated for the alignment of the synthe-
sized compounds into the 3D pharmacophore 
of erlotinib binding pose generated by 
LigandScout, this score reflects the similarity 
of the compounds to the reference pharma-
cophore. Compounds 1 and 5 showed the 
best pharmacophore score values of 116.79 
and 124.75, respectively. Furthermore, 
compounds 3 and 4 form impressive align-
ment with the erlotinib binding pose model 
with pharmacophore score values of 97.94 
and 96.20, respectively. The 3D alignment of 
compounds 1 and 5 with the pharmacophore 
model are shown in Figures 6A and 7A, 
respectively. The detailed 2D mapping of the 
pharmacophore model with the structural 
features of compounds 1 and 5 are depicted 
in Figures 6B and 7B, respectively. 
 
 
 
Figure 6: The 3D and 2D alignment of 
compound 1 with EGFR kinase pharmacophore 
model. (A) The 3D alignment of compound 1 with 
EGFR kinase pharmacophore model. (B) The 2D 
representation of the structural features in 
compound 1 that can be aligned with the 
pharmacophore hypothesis. HBA, hydrogen 
bond acceptor; HBD, hydrogen bond donor; H, 
hydrophobic center  
 
 
 
Figure 7: The 3D and 2D alignments of 
compound 5 with EGFR kinase pharmacophore 
model. (A) The 3D alignment of compound 5 with 
EGFR kinase pharmacophore model. (B) The 2D 
representation of the structural features in 
compound 5 that can be aligned with the 
pharmacophore hypothesis. HBA, hydrogen 
bond acceptor; HBD, hydrogen bond donor; H, 
hydrophobic center  
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Table 3: Results of molecular docking analysis of compounds 1-5 in the active site of EGFR-TK  
Comp. 
No. 
ReverseScreen3D Pharmacophore 
score 
Simple fitness 
Kcal/mol 
Full fitness 
Kcal/mol 2D score 3D score 
1 0.422 0.431 116.79 -7.38 -1967.63 
2 0.453 0.522 75.10 -8.06 -1960.23 
3 0.443 0.491 96.20 -7.93 -1940.36 
4 0.356 0.573 97.94 -8.61 -1942.19 
5 0.427 0.538 124.75 -8.01 -1942.13 
Erlotinib 0.421 0.516 104.29 -7.32 -1908.77 
Bold values represent the best results in each parameter. 
 
 
Docking 
The crystal structure of EGFR kinase 
domain (PDB ID: 1M17) in complex with an 
irreversible inhibitor was obtained from the 
protein data bank (PDB; http://www.rcsb.-
org/pdb/home/home.do). Docking simulation 
was done by SwissDock software (Gros-
didier et al., 2011). All the conformers were 
virtually docked at the defined cavity of the 
receptor. Regarding the results of docking, 
the dock scores of the best conformer for 
each ligand are listed (Table 3). The ligand 
forming the most stable drug receptor 
complex is the one having the least dock 
score value. The compounds are evaluated 
using two scoring functions; simple fitness 
and full fitness. Simple fitness is a fast and 
efficient method to evaluate the individual 
binding modes which neglects the solvent 
effect and is used to drive the search. 
Simultaneously, clusters of binding modes 
are evaluated by the more selective yet 
slower full fitness, which accounts for the 
solvation free energy. Compound 1, the most 
active member in the EGFR tyrosine kinase 
assay showed the best full fitness score value 
of -1967.63 Kcal/mol. 3D Interaction of 
compound 1 with the binding site of EGFR-
TK is shown in Figure 8. The docking results 
support the postulation that this compound 
may act on the same target enzyme where 
EGFR-TK inhibitors act. 
  
Figure 8: 3D Interaction of compound 1 with the 
binding site of EGFR-TK. The atoms are colored 
as following: red for oxygen atoms, blue for 
nitrogen atoms, yellow for sulfur atoms, white for 
hydrogen atoms, cyan for carbon atoms and 
green for chlorine atoms 
 
Analysis of the binding mode 
The ATP-binding pocket of EGFR-TK is 
considerably hydrophobic; thus, hydrophobic 
interaction plays an important role in affinity 
toward EGFR-TK. Moreover, it was pro-
posed that at least two hydrogen bonds are 
required for small molecules to act as EGFR-
TK inhibitors (Zuccotto et al., 2010). 
LeadIT software was used to analyze the 
location and orientation of the evaluated 
compounds and the interactions into the 
binding site of EGFR-TK. 2D Interactions of 
compounds 1 and 3 with the binding site of 
EGFR-TK are shown in Figures 9 and 10, 
respectively. The docking results (Table 4) 
revealed that the main interaction force of 
the candidate compounds with the EGFR-TK 
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active site is hydrophobic. The important 
residues in the hydrophobic regions that in-
interact with the hit compounds are (Val-
702, Leu-820 and Ala-719). All these 
residues are located near the gatekeeper 
residue Thr766 (Thr790 in alternative 
numbering in EGFR), which are the most 
common kinase-inhibitor interactions. The 
docking results showed that almost all the 
synthesized compounds are involved in at 
least two hydrogen bonding interaction with 
EGFR-TK binding site which is required for 
activity. Analysis of binding mode revealed 
that Phe-832 and Glu-738 are involved in 
hydrogen bonding interaction with 
compound 1 as it forms three hydrogen 
bonds with EGFR-TK active site, which is 
the highest possible number of hydrogen 
bonding interaction of the synthesized com-
pounds with EGFR-TK and this indicates the 
correlation between the hydrogen bonding 
interaction and the antitumor activity. 
Summary of hydrophobic interaction, 
number of hydrogen bonds and hydrogen 
bonding interacting residues of compounds 
1-5 is presented in Table 4. 
 
CONCLUSION 
In conclusion, compounds 1-5 exhibited 
more potent antitumor activity than erlotinib 
against colon cancer (HT29) and breast 
cancer (MDA-MB-231/ATCC) cell lines. In 
addition, compound 4 displayed the highest 
potency against all tested cancer cell lines 
with GI50 values in submicromolar range. 
According to the pharmacophore generated 
by LigandScout, the minimal structural 
requirements for antitumor activity consist of 
a hydrophobic region attached to 
heterocyclic ring which fits into ATP 
binding site, two hydrogen bond acceptors 
and one hydrogen bond donor. The results of 
the EGFR tyrosine kinase assay and the 
virtual screening support the postulation that 
the active compounds may act on the same 
target enzyme where EGFR-TK inhibitors 
act. These preliminary encouraging results of 
biological screening of the newly 
synthesized compounds could offer an 
excellent framework toward the discovery of 
new potent antitumor agents.  
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Figure 9: 2D Interaction of compound 1 with the 
binding site of EGFR-TK. Dashed lines represent 
hydrogen bonds. Hydrophobic interactions are 
shown by green solid lines 
 
Figure 10: 2D Interaction of compound 3 with 
the binding site of EGFR-TK. Dashed lines 
represent hydrogen bonds. Hydrophobic inter-
actions are shown by green solid lines 
 
EXCLI Journal 2014;13:573-585 – ISSN 1611-2156 
Received: February 28, 2014, accepted: May 08, 2014, published: May 26, 2014 
 
 
583 
Table 4: Summary of hydrophobic interaction, number of hydrogen bonds and hydrogen bonding 
interacting residues of compounds 1-5 
Residues involved in 
H-bond interaction 
No. of 
H-bonds 
Hydrophobic Interaction 
(within 5 Å) 
Comp. 
No. 
Glu-738, Phe-832 3 
Met-742, Thr-830, Val-702, 
Ala-719, Leu-820, Leu-694, 
Gly-772 
1 
Lys-721, Asp-831 2 Val-702, Ala-719, Lys-721, Phe-699, Leu-820, Asp-831 2 
Lys-721 3 
Thr-766, Lys-721, Ala-719, 
Leu-694, Gly-772, Val-702, 
Leu-820 
3 
Lys-721, Met-769 2 
Val-702, Leu-820, Leu-694, 
Gly-772, Pro-770, Met-769, 
Leu-768 
4 
Leu-694, Met-769 3 
Val-702, Lys-721, Leu-820, 
Leu-694, Asp-831, Phe-699, 
Ala-719 
5 
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